- Economy Sheds 533,000 Jobs, Most in 34 Years
- Citigroup Sells German Arm for $6.7 Billion
- Charts Predict S&P Festive Rally Above 1,000
- BMW's Global Sales Plunge by a Quarter in Nov.
- What the Pros Say: S&P May Fall to 700
- Bleak Jobs Data Forecasts Add to Automakers' Woes
- Euro Shares Extend Fall after US Jobs Data
- European Stocks to Open Sharply Lower
- Toshiba to Briefly Halt Chip Output on Weak Demand
- Jobs Numbers: Breakdown by Sector
- Congress And Automakers: Long And Difficult "Marriage" Ahead
- Great Companies Come at Fair Prices
- Yoshikami: Investing & the Obama Presidency
- Wall of Shame: Fortress Investment's Wes Edens
- Cramer to Geithner: Let FDIC Chair Keep Her Job
- Lightning Round: Boeing, Medtronic, Agrium and More
- Lightning Round OT: Continental, Amylin Pharma and More
- Sell Block: Cramer's Solution for Mortgage-Backed Paper Mess
Eli Lilly, Amylin and Alkermes, partners on the first-ever once-a-week drug for diabetes, announced that patients saw their blood sugar go down by two percent and their weight drop an average nine-and-a-half pounds after one year on the experimental treatment.
In addition, nearly three-quarters of the diabetics in the study got their blood sugar level at or below the recommended threshold.
The companies plan to file for FDA approval of the once-a-week Byetta—currently marketed as a twice-a-day shot—by the end of the first half of next year.
Most analysts expect it to become a multi-billion dollar blockbuster.
The CEO of Amylin [AMLN
Loading...
()
], whose shares have been hammered the past two trading days, will appear first on CNBC Tuesday morning at 10:40 a.m. ET from the American Diabetes Association meeting in San Francisco where the data were presented.
Billionaire activist investor Carl Icahn recently took a sizeable stake in Amylin.
Shares of Eli Lilly [LLY
Loading...
()
] lost 0.5 percent to close at $48.18 Monday. Alkermes stock [ALKS
Loading...
()
] declined 1.67 percent to finish at $12.36.






